Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | CETP | P11597 | 3/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
| ▸ | ALPG | P10696 | 1/20 | 0.37 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11276825 | 1.00 | TSHR (0.52) | TSHRALOX15ELANESRCCETP | |
| SCHEMBL14556164 | 0.85 | TSHR (0.55) | TSHRELANESRCCETPPDPK1 | |
| SCHEMBL206609 | 0.84 | TSHR (0.68) | TSHRELANESRCCETPPDPK1 | |
| SCHEMBL19949766 | 0.83 | IDO1 (0.40) | SMN1; SMN2IDO1 | |
| SCHEMBL731609 | 0.83 | TSHR (0.73) | TSHRALOX15SRCCETPPKM | |
| Benzene SCHEMBL28276614 | 0.82 | PKM (0.37) | TSHRALOX15PKMSMN1; SMN2CYP3A4 | |
| SCHEMBL3345886 | 0.82 | TSHR (0.52) | TSHRELANESRCCETPPDPK1 | |
| SCHEMBL16394946 | 0.80 | L3MBTL1 (0.46) | TSHRPKMSMN1; SMN2IDO1 | |
| SCHEMBL2301938 | 0.79 | TSHR (0.57) | TSHRELANESRCCETPPDPK1 | |
| SCHEMBL5379773 | 0.79 | TSHR (0.61) | TSHRELANESRCCETPPDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3510035-B1 | DUAL PROTECTED PRO-COELENTERAZINE SUBSTRATES | PROMEGA CORP (US) | 2021-04-07 | — | — | EP | disclosed |
| EP-3510035-A1 | DUAL PROTECTED PRO-COELENTERAZINE SUBSTRATES | Promega Corporation (US) | 2019-07-17 | — | — | EP | disclosed |
| US-10316070-B2 | Dual protected pro-coelenterazine substrates | PROMEGA CORPORATION (US) | 2019-06-11 | — | — | US | disclosed |
| US-20180072781-A1 | DUAL PROTECTED PRO-COELENTERAZINE SUBSTRATES | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2018-03-15 | — | — | US | disclosed |
| WO-2018049241-A1 | DUAL PROTECTED PRO-COELENTERAZINE SUBSTRATES | PROMEGA CORPORATION (US) | 2018-03-15 | — | — | WO | disclosed |
| US-8772327-B2 | Phenylpropionic acid derivative and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2014-07-08 | — | — | US | disclosed |
| US-20130131134-A1 | PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF | MORITA KOHEI (JP) | 2013-05-23 | — | — | US | disclosed |
| US-8334314-B2 | Phenylpropionic acid derivative and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-12-18 | — | — | US | disclosed |
| US-20100093819-A1 | PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-04-15 | — | — | US | disclosed |
| EP-0432688-B1 | Magnetic carrier for use in electrophotographic development | TDK CORP (JP) | 1997-03-12 | — | — | EP | disclosed |
| US-5354638-A | Magnetic carrier for use in electrophotographic development | TDK CORPORATION (JP) | 1994-10-11 | — | — | US | disclosed |
| EP-0432688-A1 | Magnetic carrier for use in electrophotographic development | TDK Corporation (JP) | 1991-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10316070-B2 | Dual protected pro-coelenterazine substrates | SI, GLB1, CTRL | TSHR 3314/4885ALOX15 2353/4885ELANE 1099/4885 |
| US-20130131134-A1 | PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF | PLA2G12A, PLA2G4A, PLA2G4B | TSHR 4126/4885ALOX15 25/4885ELANE 116/4885 |
| US-20100093819-A1 | PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF | PLA2G12A, PLA2G4A, PLA2G4B | TSHR 4126/4885ALOX15 25/4885ELANE 116/4885 |
| US-20180072781-A1 | DUAL PROTECTED PRO-COELENTERAZINE SUBSTRATES | SI, GLB1, PREP | TSHR 3501/4885ALOX15 3790/4885ELANE 1066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.